Logo-jpd
J Parathyr Dis. 2022;10: e11162 | Published on: 2022 Oct 19. doi: 10.34172/jpd.2022.11162

Original

Survival rates and prognostic factors of thyroid cancer: A retrospective cohort study

Ali Amri 1 ORCID, Ali Reza Soltanian 2 ORCID, Shiva Borzouei 3 * ORCID

Cited by CrossRef: 4

1- Yang M, Zhang Y, Li M, Liu X, Darvishi M. The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies. Cancer Cell Int. 2023;23(1) [Crossref]
2- Ghasemi Darestani N, Gilmanova A, Al-Gazally M, Zekiy A, Ansari M, Zabibah R, Jawad M, Al-Shalah S, Rizaev J, Alnassar Y, Mohammed N, Mustafa Y, Darvishi M, Akhavan-Sigari R. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun Signal. 2023;21(1) [Crossref]
3- Rezaei F, Mazidimoradi A, Pasokh Z, Dehghani S, Allahqoli L, Salehiniya H. Temporal trends of thyroid cancer between 2010 and 2019 in Asian countries by geographical region and SDI, comparison with global data. Aging Medicine. 2023;6(4):386 [Crossref]
4- Bao S, Darvishi M, H Amin A, Al-Haideri M, Patra I, Kashikova K, Ahmad I, Alsaikhan F, Al-qaim Z, Al-Gazally M, Kiasari B, Tavakoli-Far B, Sidikov A, Mustafa Y, Akhavan-Sigari R. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol. 2023;149(10):7945 [Crossref]
5- Khazaei S, Abdollahi Yeganeh S, Salim Bahrami S, Borzouei S. Evaluation of Risk Factors Associated with Recurrence and Death in Patients with Thyroid Cancer From 2008 to 2023 in the West of Iran. J Res Health Sci. 2024;24(4):e00632 [Crossref]